iBio (NASDAQ:IBIO) Announces Earnings Results, Misses Estimates By $0.01 EPS

iBio (NASDAQ:IBIO) posted its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), FiscalAI reports.

iBio Stock Performance

Shares of NASDAQ IBIO opened at $2.15 on Thursday. The company has a market capitalization of $69.96 million, a price-to-earnings ratio of -2.15 and a beta of 1.26. The business’s fifty day moving average is $2.12. iBio has a 12-month low of $0.56 and a 12-month high of $6.89.

Analyst Ratings Changes

Several brokerages have weighed in on IBIO. Leerink Partners raised iBio to a “strong-buy” rating in a research report on Friday, October 17th. Wall Street Zen upgraded shares of iBio from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of iBio in a research report on Monday, December 29th. Finally, Lifesci Capital raised iBio to a “strong-buy” rating in a research note on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy”.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.